Science Translational Medicine· Borislav Dejanovic, Matthew D. Figley, Elizabeth Weisman, Beril Kiragasi, Frederick W. Gergits, Kelley Larson, Abigail Renoux, Raj Rajagovindan, Bhaumik Pandya, Jonathan Houze, Liyue Huang, Francois Gaudreault, Ryan O’Mara, Jade H. Clarkson, Marion T. Turnbull, Andreas Meier, Marco Colonna, Jessica Stromme, David Gray, Evan A. Thackaberry, Petra Kaufmann, Christian Mirescu·· 16 小时前评分61
VG-3927/SAR448851 的临床前与首次人体评价：口服小分子 TREM2 激动剂用于阿尔茨海默病
Preclinical and first-in-human evaluation of VG-3927/SAR448851, an oral small-molecule TREM2 agonist for Alzheimer’s disease
导读
Science Translational Medicine 发表了对 VG-3927/SAR448851 的临床前与首次人体评价，该药为一款针对阿尔茨海默病的口服小分子 TREM2 激动剂。原文 DOI: 10.1126/scitranslmed.aec5740。
来源：Science Translational Medicine · science.org